KR102183910B1 - 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법 - Google Patents

항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법 Download PDF

Info

Publication number
KR102183910B1
KR102183910B1 KR1020187017681A KR20187017681A KR102183910B1 KR 102183910 B1 KR102183910 B1 KR 102183910B1 KR 1020187017681 A KR1020187017681 A KR 1020187017681A KR 20187017681 A KR20187017681 A KR 20187017681A KR 102183910 B1 KR102183910 B1 KR 102183910B1
Authority
KR
South Korea
Prior art keywords
treatment
delete delete
macular degeneration
genetic variant
anatomical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187017681A
Other languages
English (en)
Korean (ko)
Other versions
KR20180081616A (ko
KR102183910B9 (ko
Inventor
로라 퍼리
사라 하몬
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102183910(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020207012363A priority Critical patent/KR102261636B1/ko
Publication of KR20180081616A publication Critical patent/KR20180081616A/ko
Application granted granted Critical
Publication of KR102183910B1 publication Critical patent/KR102183910B1/ko
Publication of KR102183910B9 publication Critical patent/KR102183910B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Databases & Information Systems (AREA)
  • Ophthalmology & Optometry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
KR1020187017681A 2015-12-03 2016-12-01 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법 Active KR102183910B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207012363A KR102261636B1 (ko) 2015-12-03 2016-12-01 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562262589P 2015-12-03 2015-12-03
US62/262,589 2015-12-03
US201662291274P 2016-02-04 2016-02-04
US62/291,274 2016-02-04
PCT/US2016/064403 WO2017096031A1 (en) 2015-12-03 2016-12-01 Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207012363A Division KR102261636B1 (ko) 2015-12-03 2016-12-01 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법

Publications (3)

Publication Number Publication Date
KR20180081616A KR20180081616A (ko) 2018-07-16
KR102183910B1 true KR102183910B1 (ko) 2020-11-27
KR102183910B9 KR102183910B9 (ko) 2023-07-13

Family

ID=57758695

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020187017681A Active KR102183910B1 (ko) 2015-12-03 2016-12-01 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
KR1020217041649A Ceased KR20210157427A (ko) 2015-12-03 2016-12-01 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
KR1020207012363A Active KR102261636B1 (ko) 2015-12-03 2016-12-01 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
KR1020217016566A Active KR102343004B1 (ko) 2015-12-03 2016-12-01 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020217041649A Ceased KR20210157427A (ko) 2015-12-03 2016-12-01 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
KR1020207012363A Active KR102261636B1 (ko) 2015-12-03 2016-12-01 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
KR1020217016566A Active KR102343004B1 (ko) 2015-12-03 2016-12-01 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법

Country Status (22)

Country Link
US (2) US11769597B2 (https=)
EP (3) EP4559524A3 (https=)
JP (5) JP6855480B2 (https=)
KR (4) KR102183910B1 (https=)
CN (2) CN114712497B (https=)
AU (4) AU2016364817B2 (https=)
CA (3) CA3137326C (https=)
DK (1) DK3384049T3 (https=)
ES (1) ES2956007T3 (https=)
FI (1) FI3384049T3 (https=)
HR (1) HRP20231379T1 (https=)
HU (1) HUE063335T2 (https=)
IL (4) IL295808B2 (https=)
LT (1) LT3384049T (https=)
MX (3) MX2018006740A (https=)
NZ (1) NZ744025A (https=)
PL (1) PL3384049T3 (https=)
PT (1) PT3384049T (https=)
RS (1) RS64725B1 (https=)
SI (1) SI3384049T1 (https=)
SM (1) SMT202300314T1 (https=)
WO (1) WO2017096031A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017096031A1 (en) * 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
GB201805642D0 (en) * 2018-04-05 2018-05-23 Macusoft Ltd Determining a clinical outcome for a subject suffering from a macular degenerative disease
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102625384B1 (ko) 2020-09-28 2024-01-16 (주) 플라즈닉스 플라즈마 토치 및 이를 이용하여 대상기체를 처리하는 방법
JP7452892B2 (ja) * 2022-06-20 2024-03-19 株式会社ニューギン 遊技機
JP7452889B2 (ja) * 2022-06-20 2024-03-19 株式会社ニューギン 遊技機
JP7452891B2 (ja) * 2022-06-20 2024-03-19 株式会社ニューギン 遊技機
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504499A (ja) 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
DE4243524A1 (de) 1992-12-22 1994-06-23 Hoechst Ag Gemische isomerer Nonanole und Decanole, ihre Herstellung, aus ihnen erhältliche Phthalsäureester und deren Verwendung als Weichmacher
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
DE19622283A1 (de) 1996-05-23 1997-11-27 Schering Ag Verfahren zur terminalen Sterilisierung von befüllten Spritzen
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
DE19849922A1 (de) 1998-10-29 2000-05-04 Degussa Verfahren zur Behandlung von Basen und organische Säuren enthaltenden wäßrigen Lösungen
DE19849924A1 (de) 1998-10-29 2000-05-04 Degussa Verfahren zur Abtrennung organischer Säuren aus wäßrigen Lösungen
US6455743B1 (en) 1998-11-27 2002-09-24 Mitsubishi Chemical Corporation Process for producing alcohols
DE19914259A1 (de) 1999-03-29 2000-10-05 Basf Ag Verfahren zur destillativen Auftrennung eines flüssigen Rohaldehydgemisches
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
DE19933348B4 (de) 1999-07-16 2005-11-17 Oxeno Olefinchemie Gmbh Verfahren zur Reduzierung oxidischer Hydrierkontakte
US6777429B1 (en) 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition
DE19957522A1 (de) 1999-11-30 2001-05-31 Oxeno Olefinchemie Gmbh Verfahren zur katalytischen Durchführung von Aldolkondensationen mittels Mehrphasenreaktion
DE10103706A1 (de) 2001-01-26 2002-08-14 Aventis Behring Gmbh Verwendung eines Hydrogenperoxid-Plasma-Sterilisationsverfahrens für die schonende Sterilisation temperaturempfindlicher Produkte
WO2003004098A1 (en) 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
JP2005511576A (ja) 2001-11-09 2005-04-28 アイテック・ファーマシューティカルズ 眼球血管新生病を治療する方法
JP4141156B2 (ja) 2002-03-15 2008-08-27 日本ベクトン・ディッキンソン株式会社 プランジャ後退制限機構付きプレフィルドシリンジ
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
CA2519835A1 (en) 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
WO2004110490A2 (en) 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
WO2005016369A1 (en) 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
AU2005267741A1 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
JP2008520242A (ja) 2004-11-18 2008-06-19 イェール ユニバーシティ 視覚障害を処置するための方法および組成物
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
CA2615636A1 (en) 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
EP1924309A1 (en) 2005-09-16 2008-05-28 (OSI) Eyetech Inc. Ophthalmic syringe
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP1818069B1 (de) 2006-02-14 2008-09-03 Gerresheimer Bünde GmbH Verfahren zum Herstellen von vorfüllbaren Spritzen
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US20100111963A1 (en) 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
CN101600674B (zh) 2006-11-30 2013-09-11 巴斯夫欧洲公司 烯烃的加氢甲酰化方法
WO2008077155A1 (en) 2006-12-21 2008-06-26 Genentech, Inc. Sterilization of objects containing biological molecules
US20100303813A1 (en) 2007-06-08 2010-12-02 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
WO2009030976A1 (en) 2007-09-03 2009-03-12 Becton Dickinson France Medical device and smooth coating therefor
AU2009323307B2 (en) 2008-12-03 2015-02-19 Denki Kagaku Kogyo Kabushiki Kaisha Syringe
ES2600781T3 (es) * 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
DE102009001594A1 (de) 2009-03-17 2010-09-30 Evonik Oxeno Gmbh Verfahren zur Herstellung von alpha, beta-ungesättigten C10-Aldehyden
KR101191112B1 (ko) 2009-03-19 2012-10-15 주식회사 엘지화학 고순도 2-에틸헥산올 생산을 위한 분리벽형 증류탑 및 이를 이용한 분별증류방법
AR078060A1 (es) 2009-07-14 2011-10-12 Novartis Ag Descontaminacion de superficie de contenedores previamente llenados en empaque secundario
DE102009045139A1 (de) 2009-09-30 2011-03-31 Evonik Oxeno Gmbh Herstellung von alpha,beta-ungesättigten Aldehyden mittels einer Reaktionsmischpumpe
DE102009045718A1 (de) 2009-10-15 2011-04-21 Evonik Oxeno Gmbh Verfahren zur Herstellung von Decanolen durch Hydrierung von Decenalen
MX2012004306A (es) 2009-10-21 2012-04-30 Genentech Inc Polimorfismos geneticos en degeneracion macular relacionada con la edad.
CN102803189B (zh) 2010-03-15 2016-01-20 埃克森美孚化学专利公司 用于生产醇的方法
FR2966044B1 (fr) 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
US8684190B2 (en) 2010-11-19 2014-04-01 Warren Abar Multi-position solar panel rack
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
BR112013023724A2 (pt) * 2011-03-15 2019-09-24 Univ Utah Res Found métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento
WO2013106765A1 (en) * 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
DE202013000688U1 (de) 2012-07-03 2013-03-05 Novartis Ag Glas-Spritze
KR20140042402A (ko) 2012-09-28 2014-04-07 주식회사 엘지화학 올레핀으로부터 알코올의 제조장치 및 제조방법
JP5721150B2 (ja) * 2013-03-14 2015-05-20 学校法人 埼玉医科大学 加齢黄斑変性症の発症リスクの予測方法
US9926246B2 (en) 2013-05-03 2018-03-27 Saudi Basic Industries Corporation Integrated process for simultaneous production of oxo-alcohols and plasticizers
DK4374873T3 (da) 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
JP6382816B2 (ja) 2013-07-24 2018-08-29 田辺三菱製薬株式会社 眼科疾患治療剤
DE102014201756A1 (de) 2014-01-31 2015-08-06 Evonik Degussa Gmbh Reinigung chlorverschmutzter Organophosphorverbindungen
DE102014209536A1 (de) 2014-05-20 2015-11-26 Evonik Degussa Gmbh Herstellung qualitativ hochwertiger Oxo-Alkohole aus unsteten Rohstoffquellen
EP3037400B1 (de) 2014-12-23 2018-08-01 Evonik Degussa GmbH Chromfreie hydrierung von hydroformylierungsgemischen
EP3059005B1 (de) 2015-02-18 2018-10-24 Evonik Degussa GmbH Abtrennung eines homogenkatalysators aus einem reaktionsgemisch mit hilfe organophiler nanofiltration unter besonderer berücksichtigung eines membran-leistungsindikators
SG10201601501QA (en) 2015-03-05 2016-10-28 Evonik Degussa Gmbh Preparation of 2,2`-biaryls in the presence of molybdenum(v) chloride
CN104894261B (zh) * 2015-06-02 2020-02-14 北京医院 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂盒
PL3374366T3 (pl) 2015-11-09 2020-05-18 Evonik Operations Gmbh Bis-fosforyny z jednostkami 2,4-dimetylofenylowymi i ich zastosowanie jako ligandów w hydroformylowaniu
EP3170805B1 (de) 2015-11-19 2018-09-12 Evonik Degussa GmbH Beeinflussung der viskosität von auf n-buten basierenden estergemischen durch gezielten einsatz von ethen bei der herstellung der ester-vorprodukte
WO2017096031A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
ES2765635T3 (es) 2016-05-19 2020-06-10 Evonik Operations Gmbh Producción de n-pentanal a partir de mezclas de sustancias de empleo pobres en buteno
US10245578B2 (en) 2016-11-09 2019-04-02 Evonik Degussa Gmbh Chromium- and nickel-free hydrogenation of hydroformylation mixtures
DK3351526T3 (da) 2017-01-20 2021-02-08 Evonik Operations Gmbh Diisopentylterephthalat
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Graefe's Archive for Clinical and Experimental Ophthalmology (2014.11.13.) 253(9):1471-1477
Investigative Ophthalmology & Visual Science (2015.05.) 56:3279-3286*
Journal of the Korean Medical Association (2016) 59(1):52-57
Molecular Vision (2012) 18:2578-2595
Ophthalmology (2012) 119:2537-2548
Ophthalmology (2013) 120(1):115-121
Pharmacogenomics (2012) 13(9):1037-1053
The British Journal of Ophthalmology (2014) 98:i11-i16

Also Published As

Publication number Publication date
IL295808B2 (en) 2023-10-01
KR20210068154A (ko) 2021-06-08
JP7233754B2 (ja) 2023-03-07
MX2023008504A (es) 2023-07-26
CA3007276C (en) 2021-12-28
EP3384049B1 (en) 2023-08-02
CA3179836A1 (en) 2017-06-08
AU2020203362B2 (en) 2022-07-14
ES2956007T3 (es) 2023-12-11
PT3384049T (pt) 2023-08-18
HUE063335T2 (hu) 2024-01-28
JP2019503665A (ja) 2019-02-14
WO2017096031A1 (en) 2017-06-08
AU2016364817A1 (en) 2018-07-19
AU2020203362A1 (en) 2020-06-11
IL259672A (en) 2018-07-31
US20240029897A1 (en) 2024-01-25
CA3137326C (en) 2024-01-23
EP3384049A1 (en) 2018-10-10
FI3384049T3 (fi) 2023-09-25
AU2016364817B2 (en) 2020-05-07
RS64725B1 (sr) 2023-11-30
LT3384049T (lt) 2023-09-11
KR20180081616A (ko) 2018-07-16
KR102261636B9 (ko) 2023-07-13
AU2022235529B2 (en) 2025-01-23
KR20210157427A (ko) 2021-12-28
KR102343004B9 (ko) 2023-07-13
CN108474039B (zh) 2022-06-07
US20180276336A1 (en) 2018-09-27
JP2021091737A (ja) 2021-06-17
CN114712497B (zh) 2024-03-22
JP2025096332A (ja) 2025-06-26
EP4276199A2 (en) 2023-11-15
JP6855480B2 (ja) 2021-04-07
DK3384049T3 (da) 2023-10-02
JP7429318B2 (ja) 2024-02-07
IL302424B1 (en) 2024-10-01
IL259672B (en) 2022-10-01
SI3384049T1 (sl) 2023-10-30
JP7661545B2 (ja) 2025-04-14
IL295808B1 (en) 2023-06-01
NZ744025A (en) 2020-02-28
CA3007276A1 (en) 2017-06-08
IL302424A (en) 2023-06-01
AU2022235531A1 (en) 2022-10-13
EP4559524A3 (en) 2025-08-27
MX2018006740A (es) 2018-08-01
NZ761242A (en) 2024-10-25
JP2024028658A (ja) 2024-03-04
IL295808A (en) 2022-10-01
EP4276199A3 (en) 2024-04-10
PL3384049T3 (pl) 2024-01-22
KR102183910B9 (ko) 2023-07-13
SMT202300314T1 (it) 2023-11-13
IL259672B2 (en) 2023-02-01
AU2022235529A1 (en) 2022-10-13
CN114712497A (zh) 2022-07-08
AU2022235531B2 (en) 2026-02-26
IL302424B2 (en) 2025-02-01
MX2023004922A (es) 2023-05-16
NZ761246A (en) 2024-10-25
KR102261636B1 (ko) 2021-06-07
KR102343004B1 (ko) 2021-12-24
CN108474039A (zh) 2018-08-31
KR20200047779A (ko) 2020-05-07
HRP20231379T1 (hr) 2024-02-16
US11769597B2 (en) 2023-09-26
CA3137326A1 (en) 2017-06-08
JP2023053348A (ja) 2023-04-12
IL315458A (en) 2024-11-01
EP4559524A2 (en) 2025-05-28

Similar Documents

Publication Publication Date Title
KR102183910B1 (ko) 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
US12571027B2 (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
HK40102063A (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
HK40124789A (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
HK1261207B (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
HK1261207A1 (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180621

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180626

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190703

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20200116

Patent event code: PE09021S02D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200428

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200721

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200116

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20190703

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200721

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200428

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190902

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180626

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20200901

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20200820

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200721

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200428

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190902

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180626

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201123

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201124

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Patent event code: PG17011E01I

Patent event date: 20230707

Comment text: Request for Publication of Correction

Publication date: 20230713

PR1001 Payment of annual fee

Payment date: 20231023

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241029

Start annual number: 5

End annual number: 5